NO20043749L - Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II - Google Patents

Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II

Info

Publication number
NO20043749L
NO20043749L NO20043749A NO20043749A NO20043749L NO 20043749 L NO20043749 L NO 20043749L NO 20043749 A NO20043749 A NO 20043749A NO 20043749 A NO20043749 A NO 20043749A NO 20043749 L NO20043749 L NO 20043749L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
stable pharmaceutical
torsemide modification
torsemide
modification
Prior art date
Application number
NO20043749A
Other languages
English (en)
Norwegian (no)
Inventor
Judith Aronhime
Ruth Tenengauzer
Minutza Leibovici
Mira Kopel
Marko Kordova
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20043749L publication Critical patent/NO20043749L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
NO20043749A 2002-02-08 2004-09-07 Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II NO20043749L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/071,423 US20030022921A1 (en) 2001-02-21 2002-02-08 Stable pharmaceutical formulation comprising torsemide modification II
PCT/US2003/003701 WO2003066023A1 (en) 2002-02-08 2003-02-07 A stable pharmaceutical formulation comprising torsemide modification ii

Publications (1)

Publication Number Publication Date
NO20043749L true NO20043749L (no) 2004-09-07

Family

ID=27732277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043749A NO20043749L (no) 2002-02-08 2004-09-07 Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II

Country Status (16)

Country Link
US (1) US20030022921A1 (is)
EP (1) EP1359900A4 (is)
JP (1) JP2005518422A (is)
KR (1) KR20040081183A (is)
CN (1) CN1646094A (is)
AU (1) AU2003210903A1 (is)
CA (1) CA2455881A1 (is)
DE (1) DE03702168T1 (is)
ES (1) ES2209686T1 (is)
HR (1) HRP20040757A2 (is)
IS (1) IS7384A (is)
MX (1) MXPA04007695A (is)
NO (1) NO20043749L (is)
PL (1) PL372221A1 (is)
WO (1) WO2003066023A1 (is)
ZA (1) ZA200406026B (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2039349A1 (en) * 2004-10-19 2009-03-25 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising donepezil hydrochloride
CN114641278A (zh) * 2019-09-11 2022-06-17 百时美施贵宝公司 吲哚胺2,3-双加氧酶抑制剂的药物配制品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
KR20020025217A (ko) * 1999-08-11 2002-04-03 추후보정 토르세미드 동질이상
ES2193007T3 (es) * 2000-02-17 2004-11-01 Teva Pharmaceutical Industries Ltd. Formulacion farmaceutica estable que comprende la modificacion ii de la torsemida.
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide

Also Published As

Publication number Publication date
ES2209686T1 (es) 2004-07-01
WO2003066023A1 (en) 2003-08-14
US20030022921A1 (en) 2003-01-30
WO2003066023A9 (en) 2003-11-20
CA2455881A1 (en) 2003-08-14
DE03702168T1 (de) 2004-07-08
PL372221A1 (en) 2005-07-11
IS7384A (is) 2004-08-05
MXPA04007695A (es) 2004-12-07
CN1646094A (zh) 2005-07-27
EP1359900A1 (en) 2003-11-12
KR20040081183A (ko) 2004-09-20
AU2003210903A1 (en) 2003-09-02
EP1359900A4 (en) 2004-05-19
ZA200406026B (en) 2006-07-26
JP2005518422A (ja) 2005-06-23
HRP20040757A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
NO20033143L (no) Farmasoytisk preparat
NO20030418L (no) Nytt farmasöytisk preparat
PT1501534E (pt) Formulacoes farmaceuticas
KR20050009999A (ko) 약제학적 제제
NO20033556L (no) Farmasöytiske formuleringer
ATE380544T1 (de) Umhüllte feste darreichungsform
IS7298A (is) Platínuafleiða lyfjasamsetningar
NO20034026D0 (no) Nytt preparat
DE602004017700D1 (de) Transmukosen verabreichung
EE200300416A (et) Ravimvorm
NO20033042L (no) Cyklodekstrin-inneholdende farmasöytisk preparat
NO20035627D0 (no) Farmasöytisk formulering
NO20052239D0 (no) Fast preparat
NO20015149D0 (no) Nytt farmasöytisk preparat
NO20025805L (no) Farmasöytisk preparat
NO20034695L (no) Nytt preparat
NO20015148D0 (no) Nytt farmasöytisk preparat
NO20015104D0 (no) Nytt farmasöytisk preparat
NO20015105D0 (no) Nytt farmasöytisk preparat
NO20060375L (no) Famasoytisk preparat
NO20021036D0 (no) Farmasöytisk preparat
NO20041236L (no) Farmasoytisk formulering
SE0200449D0 (sv) Pharmaceutical formulation
SE0201660D0 (sv) Pharmaceutical formulation
FI20040146L (fi) Farmaseuttiset valmisteet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application